Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levornidazole Disodium Phosphate PK in Hepatic Impairment
CTR20232250Phase 4Completed
- Sponsor
- Yangtze River Pharmaceutical Group
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of levornidazole disodium phosphate in amebiasis, surgical site infection (SSI) and anaerobic infection (3 arms), sponsored by Yangtze River Pharmaceutical Group. Primary endpoints: Pharmacokinetic parameters of levornidazole and active metabolite and Safety and tolerability. Started Jul 2023; status: completed.
02
Drugs
levornidazole disodium phosphate
03
Conditions
amebiasissurgical site infection (SSI)anaerobic infection
Beyond the preview
Go deeper on CTR20232250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232250.